No needles, no preparation, no refrigeration in most cases
Keith Lafferty MD, Fort Myers on October 10, 2025
Protocol 1: Conservative foundation (beginners) Goal: Gentle immune modulation with minimal risk Components: Thymosin alpha-1: 1.6 mg subcutaneously, twice weekly BPC-157: 250 mcg subcutaneously, once daily (abdominal injection for gut support) Schedule: Monday and Thursday: Thymosin alpha-1 Daily: BPC-157 in the morning Duration: 8 weeks on, 4 weeks off Monitoring: Baseline labs before starting, repeat at week 4 and week 8
Injections: 16 syringe units/time/twice a day (injected BPC-157 must be diluted with bacteriostatic water)
In a review published last year, Sikiric and his colleagues describe BPC-157 as a drug like no other: In animal models, it counteracts symptoms akin to those of Parkinsons, Alzheimers, and schizophrenia
In murine models of metabolic syndrome and diet-induced obesity, SLU-PP-332 reduces fat mass, improves lipid parameters, and remodels liver steatosis signatures while shifting respiratory exchange ratio toward greater lipid use